Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 December;66(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 December;66(4):304-10

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  LOCAL TREATMENT OF SYNOVITIS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 December;66(4):304-10

DOI: 10.23736/S1824-4785.22.03493-8

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Current radioisotopes and radiopharmaceuticals for radiosynoviorthesis: basic and applied characteristics, production and availability

Sudipta CHAKRABORTY 1, 2, Sandip BASU 2, 3

1 Radiopharmaceuticals Division, Bhabha Atomic Research Center, Mumbai, India; 2 Homi Bhabha National Institute, Mumbai, India; 3 Radiation Medicine Center, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, India



This overview describes the basic characteristics and chemistry, production and the clinical applications and use of radiopharmaceuticals pertaining to radiosynoviorthesis (RSO). In each of the case scenarios, the physical and clinical parameters that serve as determinants and govern the choice of a particular radionuclide employed for RSO are discussed. References have been drawn on the fundamentals of RSO where applicable, including a brief review of the principles and mechanism of action, the indication and efficacy of RSO in different disease conditions and suggestions set out by the current guideline recommendations.


KEY WORDS: Synovitis; Therapeutics; Radioisotopes; Radiopharmaceuticals; chromic phosphate, 32P-labeled; Erbium-169

top of page